CD19-话题@MedSci

#CD19#

61篇内容 | 3587人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1416471, encodeId=8f3714164e104, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Nat Med：同时靶向CD19和CD22的CAR T细胞治疗复发性或难治性B细胞恶性肿瘤：I期试验 , objectType=article, longId=214902, objectId=ef3021490202, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef3021490202, replyNumber=0, likeNumber=120, createdTime=2021-07-29, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef3021490202, moduleTitle=Nat Med：同时靶向CD19和CD22的CAR T细胞治疗复发性或难治性B细胞恶性肿瘤：I期试验 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef3021490202)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416470, encodeId=79f914164e011, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=J Clin Oncol：人源CD19 CAR T细胞可使复发或难治性B-ALL患者获得持久的缓解, objectType=article, longId=213190, objectId=1a3a21319035, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a3a21319035, replyNumber=0, likeNumber=101, createdTime=2021-06-26, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a3a21319035, moduleTitle=J Clin Oncol：人源CD19 CAR T细胞可使复发或难治性B-ALL患者获得持久的缓解, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a3a21319035)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416469, encodeId=e0221416469fd, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Lancet Haematol：联合输注人源化抗CD19和抗BCMA CAR T细胞或是治疗复发或难治性多发性骨髓瘤的一种新疗法, objectType=article, longId=211074, objectId=1a872110e4ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a872110e4ea, replyNumber=0, likeNumber=89, createdTime=2021-05-12, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a872110e4ea, moduleTitle=Lancet Haematol：联合输注人源化抗CD19和抗BCMA CAR T细胞或是治疗复发或难治性多发性骨髓瘤的一种新疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a872110e4ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416468, encodeId=b238141646894, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Cancer Med：连续输注CD19-CART和BCMA CARTs可有效且安全的治疗RRMM, objectType=article, longId=210741, objectId=5562210e411f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5562210e411f, replyNumber=0, likeNumber=96, createdTime=2021-05-03, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5562210e411f, moduleTitle=Cancer Med：连续输注CD19-CART和BCMA CARTs可有效且安全的治疗RRMM, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5562210e411f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416467, encodeId=5c57141646ecc, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Bone Marrow Transplant：供体源性抗CD19的CAR-T细胞疗法可安全有效的治疗异体造血干细胞移植后复发的B-ALL, objectType=article, longId=210740, objectId=e5eb210e403b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5eb210e403b, replyNumber=0, likeNumber=63, createdTime=2021-05-03, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5eb210e403b, moduleTitle=Bone Marrow Transplant：供体源性抗CD19的CAR-T细胞疗法可安全有效的治疗异体造血干细胞移植后复发的B-ALL, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5eb210e403b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416466, encodeId=8f2c141646600, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Leuk Lymphoma：CD19 CAR T疗法可用于治疗存在T315I突变的复发性Ph+ALL患者, objectType=article, longId=210738, objectId=429f210e38af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=429f210e38af, replyNumber=0, likeNumber=96, createdTime=2021-05-03, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=429f210e38af, moduleTitle=Leuk Lymphoma：CD19 CAR T疗法可用于治疗存在T315I突变的复发性Ph+ALL患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=429f210e38af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416465, encodeId=f0981416465d3, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=恒润达生CD19/CD22双靶点CAR-T疗法获批临床, objectType=article, longId=205478, objectId=80262054e8b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80262054e8b4, replyNumber=0, likeNumber=82, createdTime=2021-01-09, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80262054e8b4, moduleTitle=恒润达生CD19/CD22双靶点CAR-T疗法获批临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=80262054e8b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416464, encodeId=435914164642a, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=ASH 2020：亘喜生物BCMA/CD19双靶向CAR-T治疗复发或难治多发性骨髓瘤首次人体治疗数据惊艳, objectType=article, longId=204260, objectId=d025204260e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d025204260e3, replyNumber=0, likeNumber=83, createdTime=2020-12-09, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d025204260e3, moduleTitle=ASH 2020：亘喜生物BCMA/CD19双靶向CAR-T治疗复发或难治多发性骨髓瘤首次人体治疗数据惊艳, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d025204260e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416463, encodeId=e762141646381, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Blood：CD19靶向CAR T细胞二次输注治疗难治性B细胞恶性肿瘤的预后及相关因素, objectType=article, longId=201329, objectId=4e25201329bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e25201329bf, replyNumber=0, likeNumber=96, createdTime=2020-09-30, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e25201329bf, moduleTitle=Blood：CD19靶向CAR T细胞二次输注治疗难治性B细胞恶性肿瘤的预后及相关因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e25201329bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416462, encodeId=a942141646285, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Blood：采用CD19/CD20 CAR T细胞治疗难治性/复发性非霍奇金淋巴瘤, objectType=article, longId=196286, objectId=035019628601, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=035019628601, replyNumber=0, likeNumber=83, createdTime=2020-06-24, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=035019628601, moduleTitle=Blood：采用CD19/CD20 CAR T细胞治疗难治性/复发性非霍奇金淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=035019628601)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416461, encodeId=089314164614e, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Blood：CD19-CAR-T细胞的内源性TCR表达的去留？, objectType=article, longId=195465, objectId=d8e3195465aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8e3195465aa, replyNumber=0, likeNumber=96, createdTime=2020-06-09, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8e3195465aa, moduleTitle=Blood：CD19-CAR-T细胞的内源性TCR表达的去留？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8e3195465aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416460, encodeId=0da7141646034, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=EMA开始审查MorphoSys的CD19单抗tafasitamab，治疗淋巴瘤, objectType=article, longId=194616, objectId=2a611946163b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a611946163b, replyNumber=0, likeNumber=127, createdTime=2020-05-24, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a611946163b, moduleTitle=EMA开始审查MorphoSys的CD19单抗tafasitamab，治疗淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a611946163b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416459, encodeId=ecf5141645948, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=CAR-T对手来了！CD19单抗tafasitamab联合来那度胺治疗淋巴瘤提交FDA上市申请, objectType=article, longId=193578, objectId=2e2f1935e8e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e2f1935e8e9, replyNumber=0, likeNumber=86, createdTime=2020-05-08, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e2f1935e8e9, moduleTitle=CAR-T对手来了！CD19单抗tafasitamab联合来那度胺治疗淋巴瘤提交FDA上市申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e2f1935e8e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416458, encodeId=21311416458c3, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=中国MNPA批准细胞疗法GC007g治疗CD19阳性复发难治B细胞急性淋巴细胞白血病的IND, objectType=article, longId=191470, objectId=27641914e046, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27641914e046, replyNumber=0, likeNumber=80, createdTime=2020-04-06, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27641914e046, moduleTitle=中国MNPA批准细胞疗法GC007g治疗CD19阳性复发难治B细胞急性淋巴细胞白血病的IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27641914e046)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416457, encodeId=dab0141645ef0, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Blood：CD19 CAT-T细胞联合依鲁替尼治疗R/R CLL的疗效和安全性, objectType=article, longId=188605, objectId=98d218860560, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=98d218860560, replyNumber=0, likeNumber=116, createdTime=2020-02-24, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98d218860560, moduleTitle=Blood：CD19 CAT-T细胞联合依鲁替尼治疗R/R CLL的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=98d218860560)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416456, encodeId=323e141645637, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=NEJM：CAR-NK细胞疗法用于CD19阳性淋巴瘤, objectType=article, longId=187581, objectId=5c3c18e5811a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c3c18e5811a, replyNumber=0, likeNumber=101, createdTime=2020-02-08, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c3c18e5811a, moduleTitle=NEJM：CAR-NK细胞疗法用于CD19阳性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c3c18e5811a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416455, encodeId=576b14164552a, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Autolus Therapeutics公布其CD19/CD22双靶CAR-T细胞疗法在大B细胞淋巴瘤中的阳性临床数据, objectType=article, longId=187159, objectId=649918e159e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=649918e159e2, replyNumber=0, likeNumber=101, createdTime=2020-02-03, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=649918e159e2, moduleTitle=Autolus Therapeutics公布其CD19/CD22双靶CAR-T细胞疗法在大B细胞淋巴瘤中的阳性临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=649918e159e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416454, encodeId=bdde14164547d, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Blood：靶向CD19和TIM3的双特异性CAR T细胞，可根除AML细胞, objectType=article, longId=186571, objectId=63611865e130, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63611865e130, replyNumber=0, likeNumber=106, createdTime=2020-01-21, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63611865e130, moduleTitle=Blood：靶向CD19和TIM3的双特异性CAR T细胞，可根除AML细胞, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63611865e130)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416453, encodeId=dfe514164539b, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=Incyte以11亿美元收购MorphoSys的抗CD19单抗tafasitamab，用于治疗B细胞淋巴瘤, objectType=article, longId=186397, objectId=d68418639efd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d68418639efd, replyNumber=0, likeNumber=97, createdTime=2020-01-18, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d68418639efd, moduleTitle=Incyte以11亿美元收购MorphoSys的抗CD19单抗tafasitamab，用于治疗B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d68418639efd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1416452, encodeId=72a114164521e, content=<a href='/topic/show?id=924442e98f' target=_blank style='color:#2F92EE;'>#CD19#</a>, objectTitle=ADC Therapeutics针对CD19的抗体偶联药物loncastuximab tesirine，在弥漫性大B细胞淋巴瘤的II期临床中大获成功, objectType=article, longId=186029, objectId=4575186029eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4575186029eb, replyNumber=0, likeNumber=52, createdTime=2020-01-11, rootId=0, userName=dingxiaobo, userId=f1583186918, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4575186029eb, moduleTitle=ADC Therapeutics针对CD19的抗体偶联药物loncastuximab tesirine，在弥漫性大B细胞淋巴瘤的II期临床中大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4575186029eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CD19

2020-05-29

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Nat Med：同时靶向CD19和CD22的CAR T细胞治疗复发性或难治性B细胞恶性肿瘤：I期试验

2021-07-29

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

J Clin Oncol：人源CD19 CAR T细胞可使复发或难治性B-ALL患者获得持久的缓解

2021-06-26

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Lancet Haematol：联合输注人源化抗CD19和抗BCMA CAR T细胞或是治疗复发或难治性多发性骨髓瘤的一种新疗法

2021-05-12

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Cancer Med：连续输注CD19-CART和BCMA CARTs可有效且安全的治疗RRMM

2021-05-03

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Bone Marrow Transplant：供体源性抗CD19的CAR-T细胞疗法可安全有效的治疗异体造血干细胞移植后复发的B-ALL

2021-05-03

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Leuk Lymphoma：CD19 CAR T疗法可用于治疗存在T315I突变的复发性Ph+ALL患者

2021-05-03

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

恒润达生CD19/CD22双靶点CAR-T疗法获批临床

2021-01-09

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

ASH 2020：亘喜生物BCMA/CD19双靶向CAR-T治疗复发或难治多发性骨髓瘤首次人体治疗数据惊艳

2020-12-09

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Blood：CD19靶向CAR T细胞二次输注治疗难治性B细胞恶性肿瘤的预后及相关因素

2020-09-30

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Blood：采用CD19/CD20 CAR T细胞治疗难治性/复发性非霍奇金淋巴瘤

2020-06-24

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Blood：CD19-CAR-T细胞的内源性TCR表达的去留？

2020-06-09

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

EMA开始审查MorphoSys的CD19单抗tafasitamab，治疗淋巴瘤

2020-05-24

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

CAR-T对手来了！CD19单抗tafasitamab联合来那度胺治疗淋巴瘤提交FDA上市申请

2020-05-08

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

中国MNPA批准细胞疗法GC007g治疗CD19阳性复发难治B细胞急性淋巴细胞白血病的IND

2020-04-06

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Blood：CD19 CAT-T细胞联合依鲁替尼治疗R/R CLL的疗效和安全性

2020-02-24

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

NEJM：CAR-NK细胞疗法用于CD19阳性淋巴瘤

2020-02-08

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Autolus Therapeutics公布其CD19/CD22双靶CAR-T细胞疗法在大B细胞淋巴瘤中的阳性临床数据

2020-02-03

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Blood：靶向CD19和TIM3的双特异性CAR T细胞，可根除AML细胞

2020-01-21

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

Incyte以11亿美元收购MorphoSys的抗CD19单抗tafasitamab，用于治疗B细胞淋巴瘤

2020-01-18

dingxiaobo (审核中...)

前往app查看评论内容

#CD19#

ADC Therapeutics针对CD19的抗体偶联药物loncastuximab tesirine，在弥漫性大B细胞淋巴瘤的II期临床中大获成功

2020-01-11

科室
- - 订阅+
  - 更多科室
工具
服务